Anti-AKR1B10 antibody

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-AKR1B10 antibody (AB96417)

ab96417, at 1/200 dilution, staining AKR1B10 in paraformaldehyde-fixed HeLa cells by Immunofluorescence. The lower image is merged with DNA probe.

• WB

Supplier Data

Western blot - Anti-AKR1B10 antibody (AB96417)

All lanes:

Western blot - Anti-AKR1B10 antibody (ab96417) at 1/5000 dilution

All lanes:

Mouse colon lysate at 50 µg

Predicted band size: 36 kDa

false

• WB

Supplier Data

Western blot - Anti-AKR1B10 antibody (AB96417)

All lanes:

Western blot - Anti-AKR1B10 antibody (ab96417) at 1/50000 dilution

All lanes:

Rat colon lysate at 50 µg

Predicted band size: 36 kDa

false

• WB

CiteAb

Western blot - Anti-AKR1B10 antibody (AB96417)

AKR1B10 western blot using anti-AKR1B10 antibody ab96417. Publication image and figure legend from Huppke, P., Weissbach, S., et al., 2017, Nat Commun, PubMed 29018201.

ab96417 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab96417 please see the product overview.

Increased stabilization and activation of mutant NRF2. a Representative western blot of endogenous level of NRF2, KEAP1, G6PD, AKR1B10 and AKR1C1 in protein lysates of human primary fibroblast cell lines from two controls (NRF2 WT 1, WT 2) and patient 1 with NRF2 p.T80K variant. Full blots are shown in Supplementary Fig. 6. b Quantitative analysis of western blot images illustrating the endogenous level of NRF2, KEAP1, G6PD, AKR1B10 and AKR1C1 relative normalized to ACTB and NRF2 WT 1. c qRT–PCR analysis of NFE2L2, KEAP1 and target gene expression in primary fibroblast cell lines from two controls (NRF2 WT 1, WT 2) and patient 1 with NRF2 p.T80K variant. AKR1B10 and AKR1C1 are visualized on a separated X axis due to the high range. Expression is normalized to that of ACTB. % of mRNA is equal to 2−∆∆CT and normalized relative to NRF2 WT 1. Redox calibration confirms full functionality of roGFP1 as well as identical response ranges for NRF2 WT 2 and NRF2 p.T80K fibroblast cells. d Response range calibration of an exemplary NRF2 WT 2 and NRF2 p.T80K fibroblast cell performed as a continuous recording of the roGFP1 ratio F395/F470 within a ROI of cytoplasm of the cell, scale bar is 20 µM. Plotted traces represent full oxidation (Rox, induced by 5 mM H2O2, 5 min) and full reduction (Rred, induced by 10 mM DTT, 5 min). After calibration the relative degrees of roGFP1 oxidation and corresponding roGFP1 redox potentials can be calculated. e Baseline redox conditions of NRF2 WT 2 and NRF2 p.T80K fibroblasts. Upper diagram shows the relative level of roGFP1 oxidation of NRF2 WT 2 and NRF2 p.T80K cells at rest (OxDroGFP1, Eq. 1). Lower diagram represents corresponding steady-state roGFP1 redox potential (EroGFP1, Eq. 2). b, c Data are given as means ± SEM, n ≥ 3 independent experiments. Data were analyzed by one-way analysis of variance with multiple comparisons : *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. e Data are given as means ± SEM. Number of measured cells are given within the bar. Statistical differences were obtained with unpaired Welch’s t-test : ***p ≤ 0.001

false